Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 52020XC0326(01)

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (OJ L 396, 30.12.2006 , p. 1.)) (Text with EEA relevance) 2020/C 99/06

C/2020/1655

OJ C 99, 26.3.2020, p. 6–6 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

26.3.2020   

EN

Official Journal of the European Union

C 99/6


Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1) )

(Text with EEA relevance)

(2020/C 99/06)

Decision granting an authorisation

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation numbers

Authorised uses

Date of expiry of review period

Reasons for the decision

C(2020)1655

19 March 2020

chromium trioxide EC No 215-607-8; CAS No 1333-82-0

HAPOC GmbH & Co KG, S.A, In der Neuen Welt 8, 87700, Memmingen, Germany

REACH/19/41/0

Use in solid form and in aqueous solution of any composition to modify the properties of surfaces made of brass or bronze for medical engineering products, exclusively for the final preparation of such surfaces and the transparent plating of an interior housing part of an anaesthesia evaporator for further incorporation into anaesthetic machines for hospitals and clinics

21 September 2029

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socioeconomic benefits outweigh the risk to human health arising from the use of the substance and there are no suitable alternative substances or technologies.


(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: http://ec.europa.eu/growth/sectors/chemicals/reach/about/index_en.htm


Top